期刊文献+

强化降脂治疗对不稳定型心绞痛患者血清高敏C反应蛋白、可溶性血管细胞黏附分子1水平的影响 被引量:3

Influence of aggressive lipid-lowering treatment on serum high-sensitive C-reactive protein and soluble vascular cell adhesion molecule-1 in patients with unstable angina
下载PDF
导出
摘要 目的探讨大剂量氟伐他汀对不稳定型心绞痛患者血清炎症因子高敏C反应蛋白(hsCRP)、可溶性血管细胞黏附分子1(sVCAM-1)水平的影响。方法将不稳定型心绞痛患者70例随机分为两组,每组各35例。A组在常规治疗基础上给予氟伐他汀40mg/d,B组在常规治疗基础上给予氟伐他汀80mg/d,用酶联免疫吸附测定法检测治疗前后血清hsCRP、sVCAM-1水平,并检测其他临床指标。结果治疗2周后,两组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)均较治疗前降低(P<0.05),但组间比较差异无统计学意义(P>0.05);两组治疗后hsCRP、sVCAM-1浓度均比治疗前降低(P<0.01),治疗后两组比较差异有统计学意义(P<0.01),治疗后A组和B组分别为hsCRP(10.52±1.76)mg/L vs(7.79±1.53)mg/L;sVCAM-1(441.18±87.06)μg/L vs(347.91±94.25)μg/L;hsCRP、sVCAM-1下降与LDL-C、TC下降无相关性(P>0.05)。结论强化降脂治疗能明显抑制不稳定型心绞痛患者的炎症反应,降低血清hsCRP和sVCAM-1水平,氟伐他汀的抗炎作用独立于降脂作用以外。 Objective To study the influence of the high dose fluvastatin on serum inflammation cytokines highsensitive C-reactive protein(hsCRP) and soluble vascular cell adhesion molecule-1(sVCAM-1) concentrations in patients with unstable angina(UA). Methods Seventy patients with UA were randomly divided into two groups to accept fluvastatin 40 mg daily as group A(n=35),or fluvastatin 80 mg daily as group B(n=35) at the base of routine therapy.Enzyme-linked immunosorbent assay(ELISA) was used to detect the serum concentrations of hsCRP and sVCAM-1 of all patients before and after therapy,other clinical indexes were also tested. Results The concentrations of TC and LDL-C were decreased after two weeks of treatment in both groups compared to those before treatment(P0.05),but there were no significant difference after therapy between two groups(P0.05).The concentrations of hsCRP and sVCAM-1 were significantly decreased after treatment in both groups compared to those before treatment(P0.01),and there were significant difference after therapy between two groups(P0.01),hsCRP(10.52±1.76) mg/L vs(7.79±1.53) mg/L in group A than in group B,sVCAM-1(441.18±87.06) μg/L vs(347.91±94.25) μg/L in group A than in group B.The reductions of hsCRP and sVCAM-1 were not related to the changes of TC and LDL-C(P0.05). Conclusion Aggressive lipid-lowering treatment can inhibit inflammation reaction and decrease the serum concentrations of hsCRP and sVCAM-1 in patients with UA.The anti-inflammation of fluvastatin has no correlation with its lipids suppression.
出处 《临床荟萃》 CAS 2011年第20期1759-1761,共3页 Clinical Focus
关键词 心绞痛 不稳定型 氟伐他汀 C反应蛋白质 血管细胞黏附分子1 angina unstable fluvastatin C-reactive protein vascular cell molecule-1
  • 相关文献

参考文献10

二级参考文献45

  • 1刘玲,赵水平,李全忠,胡敏,李冀香,程艳春.心血管事件高危患者餐后高敏C反应蛋白浓度变化及氟伐他汀干预的影响[J].中华心血管病杂志,2004,32(7):603-605. 被引量:12
  • 2苏华,杜优优,潘宏伟,刘厂辉,周胜华.阿托伐他汀对急性冠状动脉综合征患者PCI术后炎症因子的影响[J].临床荟萃,2007,22(3):155-158. 被引量:3
  • 3Ridker PM, Danielson E, Fonseca FA, Genest J, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med, 2008,359 (21):2195-2207.
  • 4Chan KY,Boucher ES, Gandhi PJ, et al. HMG-CoA reductase inhihitors for lowering elevated levels of C-reative protein[J]. Am J Health Syst Pharm,2004,61(16):1676-1681.
  • 5LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J]. N Engl J Med, 2005,352 (14) :1425-1435.
  • 6Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association [ J ]. Circulation, 2003,107 (3) :499-511.
  • 7Verma S,Szmitko PE, Ridker PM. C-reactive protein comes of age[J]. Nat Clin Praet Cardiovase Med, 2005,2 (1) : 29-36.
  • 8Rosenson RS,Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction [J]. JAMA, 1998,279(20) :1643-1650.
  • 9Ridker PM, Rifai N, Clearfield M, et al. Measurement of C- reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events[J]. N Engl J Med, 2001,344 (26) : 1959-1965.
  • 10SEARCH Study Collaborative Group,Bowman L, Armitage J, Bulbulia R, et al. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors[J] Am Heart J, 2007,154(5) : 815-823.

共引文献51

同被引文献31

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部